Cytokinetics
Trade Cytokinetics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About CYTK
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility.
CYTK Key Statistics
Stock Snapshot
The current Cytokinetics(CYTK) stock price is $68.26, with a market capitalization of 8.34B. The stock trades at a price-to-earnings (P/E) ratio of -10.77.
On 2026-02-23, Cytokinetics(CYTK) stock traded between a low of $67.55 and a high of $68.92. Shares are currently priced at $68.26, which is +1.1% above the low and -1.0% below the high.
Cytokinetics(CYTK) shares are trading with a volume of 1.48M, against a daily average of 1.7M.
In the last year, Cytokinetics(CYTK) shares hit a 52-week high of $70.98 and a 52-week low of $29.31.
In the last year, Cytokinetics(CYTK) shares hit a 52-week high of $70.98 and a 52-week low of $29.31.
CYTK News
RBC Capital raised the firm’s price target on Cytokinetics (CYTK) to $101 from $95 and keeps an Outperform rating on the shares. On the likelihood of success fo...
European Commission approves MYQORZO (aficamten) for symptomatic obstructive hypertrophic cardiomyopathy in adults across the EU. The decision follows Phase 3...
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All...
Analyst ratings
81%
of 21 ratingsMore CYTK News
Cytokinetics ( (CYTK) ) just unveiled an update. Cytokinetics, Incorporated announced that the European Commission has approved MYQORZO (aficamten) tablets in...
Cytokinetics (CYTK) announced that the European Commission, EC, has approved Myqorzo, 5 mg, 10 mg, 15 mg and 20 mg tablets for the treatment of symptomatic obst...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.